Federal Drug Administration approves Alzheimer’s blood test for use in primary care
1. The FDA has cleared the first Alzheimer’s blood test for community use, marking a pivotal step toward earlier and less invasive diagnosis.
2. Roche and Lilly’s Elecsys pTau181 assay achieved a 97.9 percent negative predictive value and could screen over one million Americans within its first year.
The FDA has approved a new blood test for Alzheimer’s disease, marking one of the most important advances in dementia diagnostics in decades. Developed by Roche and Eli Lilly, the Elecsys pTau181 assay measures a phosphorylated form of the tau protein that signals amyloid buildup in the brain. In pivotal studies, the test achieved a 97.9 percent negative predictive value for ruling out Alzheimer’s disease. Historically, confirming amyloid pathology required PET scans costing up to $7,000 or spinal fluid analysis, both of which limited access to testing. The Elecsys assay can be run in standard laboratories, giving primary care physicians new capability to identify patients at risk. More than six million Americans currently live with Alzheimer’s, and that number is expected to rise to nearly 13 million by 2050. The FDA’s October 13 decision could bring this test to clinics nationwide by early 2026. Experts note that biomarker positivity does not automatically equal a diagnosis and that results should complement cognitive assessments. For patients, the test could shorten diagnostic timelines that often exceed two years from symptom onset. Medicare is reviewing coverage options that could make the test available for less than $250. For clinicians, it means earlier, data-driven discussions about memory loss, prognosis, and treatment planning. The assay’s approval also reflects how precision neurology is becoming integrated into routine lab workflows. It signals the start of a new diagnostic era for a disease that affects one in nine older adults in the United States.
Image: PD
©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
